Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr;18(4):932-8.
doi: 10.1245/s10434-010-1390-8.

Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer

Abigail S Caudle  1 , Ana M Gonzalez-Angulo, Kelly K Hunt, Lajos Pusztai, Henry M Kuerer, Elizabeth A Mittendorf, Gabriel N Hortobagyi, Funda Meric-Bernstam
Affiliations

Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer

Abigail S Caudle et al. Ann Surg Oncol. 2011 Apr.

Abstract

Background: Although neoadjuvant chemotherapy (NCT) is standard therapy for locally advanced breast cancer, it remains controversial for early-stage disease due to concerns that disease progression may make breast-conservation therapy (BCT), or even operability, impossible. The goal of this study was to determine the impact of disease progression during NCT on surgical management.

Methods: We reviewed clinicopathological data on patients who received NCT for stage I-III breast cancer from 1994 to 2007. Chemotherapy regimens were anthracycline-and/or taxane-based as determined by the treating medical oncologist.

Results: Of 1,928 patients who received NCT, 1,762 (91%) had a partial or complete response, 107 (6%) had stable disease (SD), and 59 (3%) progressed (PD) while receiving at least one regimen. Of the patients with progressive disease, 40 (68%) patients underwent mastectomy, 12 (20%) underwent BCT, and 7 (12%) did not undergo surgery. In patients who underwent mastectomy, only three (8%) were BCT candidates before progression. Overall, disease progression changed the operative plan in 11 (0.5%) patients: 3 developed distant metastasis, 2 developed clinical lymphadenopathy, 3 required mastectomy instead of BCT, 2 became inoperable, and 1 required flap closure.

Conclusions: Disease progression while receiving NCT is infrequent (3%), but early identification may allow for change to other, potentially beneficial, therapeutic interventions. Patients with breast cancer who receive NCT should be evaluated frequently for response to therapy. Overall, progression during NCT changes the surgical management in a small proportion of patients.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
a Patients who received a taxane-based regimen as their first chemotherapy regimen. b Patients who received an anthracycline-based regimen as their first chemotherapy regimen
FIG. 2
FIG. 2
Timing of progression on NCT
See this image and copyright information in PMC

Comment in

References

    1. Hunt K, Yi M, Mittendorf E, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009 - PubMed
    1. Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. - PubMed
    1. Caudle A, Gonzalez-Angulo A, Hunt K, et al. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28:1821–28. - PMC - PubMed
    1. Fisher B, Bryant J, Wolmark N, et al. Effect of pre-operative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–85. - PubMed
    1. van Nes J, Putter H, Julien J, et al. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. Breast Cancer Res Treat. 2009;115:101–13. - PubMed

Publication types

MeSH terms